|On January 18, 2018, the Institute for Safe Medication Practices Canada (ISMP Canada) posted an online questionnaire to seek input from healthcare providers, consumers, and other interested and affected stakeholders on different approaches to the naming of biologic drugs, including biosimilars, in Canada. ASBM submitted comments on February 9th advocating the use of 4-letter suffixes, an approach favored by the WHO and FDA.
The questionnaire was developed collaboratively with Health Canada. Administration of the questionnaire and analysis of responses will be performed by ISMP Canada.
The objective of the consultation was to gain insight into stakeholder views on the practical impacts of different approaches to the naming of biologic drugs and biosimilars throughout the medication-use process, including prescribing, dispensing, and adverse drug reaction reporting.
Results of the consultation will be used to:
The questionnaire suggested three options for consideration: